AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma

Lijuan Zhang, Shili Zhan, Fariba Navid, Qingdi Li, Yung Hyun Choi, Min Kim, Prem Seth, Lee J. Helman

Research output: Contribution to journalArticle

Abstract

The human insulin-like growth factor II gene is regulated in a development-dependent manner and is not expressed in most adult tissues. However, high levels of insulin-like growth factor II mRNA are detected in many human tumors including rhabdomyosarcoma, an embryonal tumor of skeletal muscle origin. In this study, we demonstrate that the developmentally regulated transcription factor AP-2 is expressed at higher levels in human fetal skeletal muscle and rhabdomyosarcoma cells compared to human adult skeletal muscle. Endogenous insulin-like growth factor II mRNA derived from the P3 as well as transfected P3 promoter activity were modestly and consistently increased to the same extent following treatment of the rhabdomyosarcoma cell line RD with forskolin, a compound implicated in AP-2 transactivation. This effect of AP-2 on increased transcriptional activity was confirmed by nuclear run-on assays. Expression of AP-2B, a dominant-negative inhibitor of AP-2, suppressed the P3 promoter activity in AP-2 expressing RD cells. Furthermore, five AP-2 protected regions corresponding to six AP-2 specific binding sites were detected in the insulin-like growth factor II P3 promoter. These data together suggest that AP-2 may contribute to the high expression of IGF-II in rhabdomyosarcoma cells.

Original languageEnglish (US)
Pages (from-to)1261-1270
Number of pages10
JournalOncogene
Volume17
Issue number10
DOIs
StatePublished - Sep 10 1998

    Fingerprint

Keywords

  • AP-2
  • IGF-II
  • Tumor cells

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Zhang, L., Zhan, S., Navid, F., Li, Q., Choi, Y. H., Kim, M., Seth, P., & Helman, L. J. (1998). AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma. Oncogene, 17(10), 1261-1270. https://doi.org/10.1038/sj.onc.1202050